Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Akt is a serine/threonine kinase and it participates in the key role of the PI3K signaling
pathway. The Akt can be activated by a wide range of growth signals and the biochemical …

The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in
the past few decades. As of today, there are six CAR T cell products that have been …

Unlimited generation of chimeric antigen receptor (CAR) T cells from human-induced
pluripotent stem cells (iPSCs) is an attractive approach for" off-the-shelf" CAR T cell …

The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is
highly dependent on their differentiation status. It is now apparent that less differentiated T …

Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach
in treating hematological malignancies. CAR T-cells represent engineered autologous T …

Adoptive immunotherapies using T cells genetically redirected with a chimeric antigen
receptor (CAR) or T cell receptor (TCR) are entering mainstream clinical practice. Despite …

Metformin has been studied for its anticancer effects by regulating T cell functions. However,
the mechanisms through which metformin stimulates the differentiation of memory T cells …

Immune checkpoint inhibitors and adoptive T cell therapies have been valuable additions to
the toolbox in the fight against cancer. These treatments have profoundly increased the …

In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led
to a cellular immunotherapy revolution against various cancers. Although CAR-T cell …